About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
FGEN - FibroGen| Previous Close | $13.05 | Open | $13.20 |
| Volume | 543.3K | Market Cap | 1.205B |
| Yield | Last Dividend |
| The Daily Biotech Pulse: ObsEva Surges O... | 07/27/21 |
| Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Ab... | |
| Moderna headlines weekly healthcare gain... | 07/17/21 |
| No summary available. | |
| Services - Moderna, State Street rise; F... | 07/16/21 |
| Stocks that traded heavily or had substantial price changes Friday: Moderna Inc., up $26.76 to $286.43. The biotechnology company will replace Alexion... | |
| Moderna, State Street rise; FibroGen, Ma... | 07/16/21 |
| Stocks that traded heavily or had substantial price changes Friday: Moderna, State Street rise; FibroGen, Marten Transport fall | |
| Here''s Why FibroGen Stock Is Plunging T... | 07/16/21 |
| An FDA advisory committee made it clear that they don''t want the agency to approve roxadustat due to safety concerns. | |
| FibroGen Analyst Removes Roxadustat Sale... | 07/16/21 |
| FibroGen, Inc. (NASDAQ: FGEN ) shares were slumping over 40% following a negative AdCom verdict and a string of downgrades in reaction to the adverse ... | |
| FDA advisers push back on FibroGen anemi... | 07/16/21 |
| Safety worries led to a near-unanimous vote against roxadustat in kidney disease patients, dimming the approval chances of what would be the first pil... | |
| FGEN Stock Collapses After FDA Panel Rej... | 07/16/21 |
| The post FGEN Stock Collapses After FDA Panel Rejects Anemia Treatment appeared on BitcoinEthereumNews.com . A Food and Drug Administration panel vote... | |
| FGEN Stock: The Huge FDA News Causing Fi... | 07/16/21 |
| InvestorPlace - Stock Market News, Stock Advice & Trading Tips FibroGen (FGEN) stock is falling hard on Friday after the company received the results ... | |
| China SXT Pharmaceuticals, Trinity Biote... | 07/16/21 |
| No summary available. | |
| Fibrogen continues plunge amid FDA panel... | 07/16/21 |
| No summary available. | |
| FibroGen Stock Collapses After FDA Panel... | 07/16/21 |
| A FDA panel voted resoundingly against recommending approval for an anemia treatment from FibroGen, and FGEN stock tanked on Friday. | |
| STAT+: Pharmalittle: ICER medical expert... | 07/16/21 |
| An FDA expert panel concluded that risks of blood clots and other safety concerns tied to Fibrogens anemia pill were too high to support the drugs app... | |
| FibroGen hurt by downgrades, Danaher giv... | 07/16/21 |
| No summary available. | |
| : FibroGen stock price target cut to $18... | 07/16/21 |
| This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the ... | |
| AstraZeneca says FDA advisory committee ... | 07/16/21 |
| AstraZeneca PLC undefinedundefined has disclosed Friday that a U.S. Food and Drug Administration advisory committee has voted 13 to 1 not to support a... | |
| The Daily Biotech Pulse: Galapagos Sinks... | 07/15/21 |
| Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Al... | |
| FibroGen stock trading halted ahead of F... | 07/15/21 |
| No summary available. | |
| FibroGen slides after FDA posted documen... | 07/13/21 |
| No summary available. | |
| FibroGen Appoints John Hunter, Ph.D. as ... | 07/12/21 |
| SAN FRANCISCO, July 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chi... | |
| Stock market grows more optimistic | 07/04/21 |
| Stock market investors will be watching out for the June inflation figure to be released this week while becoming more optimistic as COVID-19 start to... | |
| Stock market more optimistic | 07/04/21 |
| Stock market investors will be watching out for the June inflation figure to be released this week while becoming more optimistic as COVID-19 starts t... | |
| European Regulators Suggest Approval of ... | 06/25/21 |
| European regulators issued a positive recommendation on FibroGen''s key drug roxadustat, which has had major setbacks in its path to approval in the U... | |
| Astellas Receives Positive CHMP Opinion ... | 06/25/21 |
| TOKYO, June 25, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Na... | |
| Astellas Receives Positive CHMP Opinion ... | 06/25/21 |
| TOKYO, June 25, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq... | |
| Fibrogen shares rise 6% on positive CHMP... | 06/25/21 |
| No summary available. | |
| FibroGen is facing a milestone this week... | 06/22/21 |
| No summary available. | |
| Fibrogen licensing multiple preclinical ... | 06/22/21 |
| Just days after Hifibio Therapeutics Inc. closed a $75 million series D financing, Fibrogen Inc. has agreed to pay the antibody specialist $25 million... | |
| Ilijan, First Gen plants affected with M... | 06/22/21 |
| As gas restriction predicament at the Malampaya field recurred on Monday (June 21), the countrys gas plants have been adversely impacted anew on their... | |
| Unpopular power firms could be popular s... | 06/20/21 |
| During the past 12 months, the performance of listed power generation companies has been mixed. Clean energy companies First Gen and AC Energy have pe... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Momentum Stocks Only | Hao | 46.00 % | Subscribe |
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
| cerevisiology | John Cho | 19.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
